Recurrent Melanoma Terminated Phase 2 Trials for Axitinib (DB06626)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01533948Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by SurgeryTreatment